Cyp39a1-flox Mouse
Common Name
Cyp39a1-flox
제품 ID
S-CKO-11933
Backgroud
C57BL/6NCya
품종 계통계통 ID
CKOCMP-56050-Cyp39a1-B6N-VA
상태
이 마우스 계통을 논문에서 사용할 경우, “Cyp39a1-flox Mouse (카탈로그 번호 S-CKO-11933)은 Cyagen에서 구입하였습니다.”라고 명시해 주시기 바랍니다.
구매 가능한 제품 종류
연령
Genotype
성별
수량
표준 제공 조건은 최소 3마리의 이형접합(heterozygous) 보균자를 보장합니다. 동형접합(homozygous) 보균자 및/또는 특정 성별에 대한 브리딩 서비스도 제공됩니다.
기본 정보
품종 계통
Cyp39a1-flox
품종 계통계통 ID
CKOCMP-56050-Cyp39a1-B6N-VA
유전자명
제품 ID
S-CKO-11933
유전자 별칭
mCYP39A1
배경
C57BL/6NCya
NCBI ID
변형 내용
Conditional knockout
염색체
Chr 17
Phenotype
Datasheet
적용 분야
--
품종 계통 설명
Ensembl 전사체 ID
ENSMUST00000170988
NCBI 전사체 ID
NM_018887
타겟 영역
Exon 3
유효 영역 크기
~0.7 kb
유전자 연구 개요
CYP39A1, a member of the cytochrome P450 family, functions as an oxysterol 7α -hydroxylase, selectively catalyzing the 7α -hydroxylation of 24 -hydroxycholesterol [8,9]. It is involved in the alternative bile acid synthesis pathway in the liver and is also expressed in the ciliary nonpigmented epithelium of the eye, suggesting a role in ocular sterol metabolism [9]. It may be regulated by the orphan nuclear receptor RORα, and abnormal expression can lead to the accumulation of 24S -OHC, influencing neurodegenerative disease-related deterioration [7].
In hepatocellular carcinoma (HCC), CYP39A1 protein and mRNA expression are downregulated compared to non-cancerous liver tissues. Overexpression of CYP39A1 inhibits HepG2 and SMMC-7721 cell viability, while knockout promotes HCC cell growth, indicating it may act as a tumor suppressor gene [1].
In exfoliation syndrome, carriers of functionally deficient CYP39A1 mutations have a significantly increased risk of glaucoma and blindness, and those with the CYP39A1 G204E mutation have a higher incidence of exfoliation glaucoma and more severe glaucoma [2,3].
In high-altitude pulmonary edema (HAPE), the methylation level of CYP39A1 is associated with the risk of HAPE in the Chinese population, with certain CpG sites having either a protective or risk-increasing role [4].
In advanced head and neck cancer, the CYP39A1 rs7761731 polymorphism is associated with a higher incidence of leucopenia and infections or death during intensive induction chemotherapy [5].
In cholangiocarcinoma, low CYP39A1 expression is correlated with metastasis and poor prognosis [6].
In conclusion, CYP39A1 plays diverse roles in multiple biological processes and disease conditions. Its downregulation in HCC, association with glaucoma in exfoliation syndrome, and link to HAPE risk, among others, highlight its significance. Gene knockout and related functional studies in various models contribute to understanding its role in these diseases, potentially providing new directions for disease diagnosis, prevention, and treatment [1-6].
References:
1. Li, Dan, Yu, Tao, Hu, Junjie, Gu, Lijuan, Zeng, Zhi. 2021. Downregulation of CYP39A1 Serves as a Novel Biomarker in Hepatocellular Carcinoma with Worse Clinical Outcome. In Oxidative medicine and cellular longevity, 2021, 5175581. doi:10.1155/2021/5175581. https://pubmed.ncbi.nlm.nih.gov/35003516/
2. Bell, Katharina, Ozaki, Mineo, Mori, Kazuhiko, Khor, Chiea Chuen, Aung, Tin. 2021. Association of the CYP39A1 G204E Genetic Variant with Increased Risk of Glaucoma and Blindness in Patients with Exfoliation Syndrome. In Ophthalmology, 129, 406-413. doi:10.1016/j.ophtha.2021.11.001. https://pubmed.ncbi.nlm.nih.gov/34763023/
3. Li, Zheng, Wang, Zhenxun, Lee, Mei Chin, Tam, Wai Leong, Khor, Chiea Chuen. . Association of Rare CYP39A1 Variants With Exfoliation Syndrome Involving the Anterior Chamber of the Eye. In JAMA, 325, 753-764. doi:10.1001/jama.2021.0507. https://pubmed.ncbi.nlm.nih.gov/33620406/
4. Wang, Pingyi, Lu, Hongyan, Rong, Hao, He, Yongjun, Jin, Tianbo. 2023. The Association of Methylation Level in the CYP39A1 Gene with High Altitude Pulmonary Edema in the Chinese Population. In Pharmacogenomics and personalized medicine, 16, 617-628. doi:10.2147/PGPM.S397862. https://pubmed.ncbi.nlm.nih.gov/37366513/
5. Melchardt, Thomas, Hufnagl, Clemens, Magnes, Teresa, Greil, Richard, Egle, Alexander. 2015. CYP39A1 polymorphism is associated with toxicity during intensive induction chemotherapy in patients with advanced head and neck cancer. In BMC cancer, 15, 725. doi:10.1186/s12885-015-1776-x. https://pubmed.ncbi.nlm.nih.gov/26475344/
6. Khenjanta, Chakkaphan, Thanan, Raynoo, Jusakul, Apinya, Pairojkul, Chawalit, Yongvanit, Puangrat. . Association of CYP39A1, RUNX2 and oxidized alpha-1 antitrypsin expression in relation to cholangiocarcinoma progression. In Asian Pacific journal of cancer prevention : APJCP, 15, 10187-92. doi:. https://pubmed.ncbi.nlm.nih.gov/25556446/
7. Matsuoka, Hiroshi, Katayama, Miyu, Ohishi, Ami, Shima, Akiho, Michihara, Akihiro. 2020. Orphan Nuclear Receptor RORα Regulates Enzymatic Metabolism of Cerebral 24S-Hydroxycholesterol through CYP39A1 Intronic Response Element Activation. In International journal of molecular sciences, 21, . doi:10.3390/ijms21093309. https://pubmed.ncbi.nlm.nih.gov/32392803/
8. Grabovec, I P, Smolskaya, S V, Baranovsky, A V, Usanov, S A, Strushkevich, N V. 2019. Ligand-binding properties and catalytic activity of the purified human 24-hydroxycholesterol 7α-hydroxylase, CYP39A1. In The Journal of steroid biochemistry and molecular biology, 193, 105416. doi:10.1016/j.jsbmb.2019.105416. https://pubmed.ncbi.nlm.nih.gov/31247323/
9. Ikeda, Hiromi, Ueda, Masamichi, Ikeda, Masataka, Kobayashi, Hiroshi, Honda, Yoshihito. . Oxysterol 7alpha-hydroxylase (CYP39A1) in the ciliary nonpigmented epithelium of bovine eye. In Laboratory investigation; a journal of technical methods and pathology, 83, 349-55. doi:. https://pubmed.ncbi.nlm.nih.gov/12649335/
품질 관리 기준
정자 검사
동결 보존 전: 정자 농도 측정 및 정자 생존율 평가.
동결 보존 후: 각 배치에서 동결 보존된 정자 바이알 1개를 선택하여 체외수정(in vitro fertilization)에 사용합니다.
Environmental Standards:
SPFAvailable Region:
GlobalSource:
Cyagen문의하기
맞춤형 동물 모델 관련 상담을 위해 Cyagen 전문가와 연락해 보세요. 아래 양식을 작성하여 상담을 시작하거나 견적을 요청하시기 바랍니다.
Cyagen은 고객님의 개인정보를 소중히 여깁니다. 최신 제품, 서비스 및 인사이트를 안내드리고자 합니다. 고객님의 수신 설정은 다음과 같습니다:
해당 커뮤니케이션은 언제든지 수신 거부하실 수 있습니다. 수신 거부 방법 및 데이터 보호에 대한 자세한 내용은 개인정보처리방침을 참고해 주시기 바랍니다.
아래 버튼을 클릭함으로써, 요청하신 콘텐츠 제공을 위해 본 양식을 통해 제출된 개인정보를 Cyagen이 저장 및 처리하는 데 동의하게 됩니다.
